Web Results


Find out more about Eon Labs, Inc. including an overview, stats, history and other Pharmaceuticals and Biotechnology competitors.


Eon Labs, Inc. develops, licenses, manufactures, sells, and distributes pharmaceutical products. The Company focuses on drugs in various solid oral dosage forms, utilizing both immediate and sustained release delivery, in tablet, multiple layer tablet, film-coated tablet, and capsule forms. Eon Labs serves the United States ...


Eon Labs, Inc. is a generic drug manufacturer that develops, manufactures, and markets a broad range of prescription pharmaceutical products. The company focuses on drugs that are difficult to make and it strives to introduce the generic equivalent of brand name drugs on the first day patent protection expires.


Our Work · What We Do · Disease Areas · Quality Generics · Biosimilars · About Us · Who We Are · Where We Do Business · Corporate Responsibility · Doing Business Responsibly · For Novartis Investors · Contact Us · Patients & Customers · Product Catalog · Report Side Effects · Product Safety Notices · Information for ...


Company Name, EON LABS INC. Company Address, 787 SEVENTH AVE NEW YORK, NY 10019. Company Phone, 2127288116. Company Website, www. eonlabs.com. CEO, Bernhard Hampl, Ph.D. Employees (as of 3/31/2002), 355. State of Inc, DE. Fiscal Year End, 12/31. Status, Priced (5/23/2002). Proposed Symbol ...


Learn about working at Eon Labs. Join LinkedIn today for free. See who you know at Eon Labs, leverage your professional network, and get hired.


Eon Labs, Inc. is in the Pharmaceutical Preparations business. View competitors, revenue, employees, website and phone number.


Feb 22, 2010 ... WASHINGTON – Eon Labs Inc. has agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company's drug Nitroglycerin Sustained Release (SR) capsules, the Justice Department announced today. Eon Labs is a subsidiary of Sandoz Inc., which is in turn a ...


Aug 12, 2010 ... King Pharmaceuticals Last week, in King Pharmaceuticals, Inc. v. Eon Labs, Inc., the Federal Circuit affirmed a grant of summary judgment of invalidity of U.S. Patent Nos. 6,407,128 (the "'128 patent") and 6,683,102 (the "'102 patent"), although not necessarily for the same reasons articulated by the U.S. ...